by mpzzqmvj | Jun 21, 2021 | Press Releases
Company to discuss clinical progress of Trappsol® Cyclo™ development program for the treatment of Niemann-Pick Disease Type C (NPC) GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the...
by mpzzqmvj | Jun 17, 2021 | Press Releases
Global clinical protocol agreed upon by US Food and Drug Administration (FDA) and European MedicinesAgency (EMA) GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage...
by mpzzqmvj | Jun 15, 2021 | Press Releases
– Company dedicated to developing life-changing medicines through science and innovation for patients and families living with challenging diseases- Pivotal Phase 3 study of Trappsol® Cyclo™ for Niemann-Pick Disease Type C (NPC) on track to commence...
by mpzzqmvj | Jun 14, 2021 | Press Releases
GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and...
by mpzzqmvj | Jun 9, 2021 | Press Releases
Live video webcast presentation with members of the Company’s executive leadership team on Thursday, June 17th at 12:30 PM ETGAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a...
